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Abstract 21 
The aim of this study was to evaluate if the treatments with ceftiofur and amoxicillin are 22 
risk factors for the emergence of cephalosporin resistant (CR) E. coli in a pig farm 23 
during the rearing period. 100 seven-day-old piglets were divided into two groups, 24 
control (n=50) and parenterally treated with ceftiofur (n=50). During the fattening 25 
period, both groups were subdivided in two. A second treatment with amoxicillin was 26 
administered in-feed to two of the groups; group 1 (untreated, n=20), group 2 (treated 27 
with amoxicillin, n=26), group 3 (treated with ceftiofur, n=20) and group 4 (treated with 28 
ceftiofur and amoxicillin, n=26). During treatment with ceftiofur faecal samples were 29 
collected before treatment (day 0) and at days 2, 7, 14, 21 and 42 post-treatment, 30 
whereas with amoxicillin, the sampling was extended 73 days post-treatment. CR E. 31 
coli were selected on MacConkey agar with ceftriaxone (1mg/L). PFGE, minimal 32 
inhibitory concentration to 14 antimicrobials, presence of cephalosporin resistance 33 
genes and replicon typing of plasmids were analyzed. Both treatments generated an 34 
increase in the prevalence of CR E. coli, which was statistically significant in the treated 35 
group. Resistance diminished after treatment. A total of 47 CR E. coli were recovered 36 
during the study period, 15 contained blaCTX-M-1, 10 blaCTX-M-14, four blaCTX-M-9, two 37 
blaCTX-M-15 and five blaSHV-12. By the finishing time, all animals were negative for CR E. 38 
coli. The treatment with ceftiofur and amoxicillin was associated to the emergence of 39 
CR E. coli, however did not pose enough selective pressure to select for long-term 40 
resistant organisms.  41 
 42 
 43 
 
 
Introduction 44 
The major issues of veterinary practitioners when treating a large population of animals 45 
are to maximize the likelihood of a favourable clinical outcome at the population level, 46 
and to minimize the emergence and development of antimicrobial resistance that could 47 
compromise future treatments. When new antimicrobials are introduced on the market, 48 
resistant bacteria for which the active substance used to show an excellent activity could 49 
quickly emerge. This process should be considered a natural phenomenon, since the 50 
antimicrobial would be the factor that determines which strain of each bacterium will be 51 
the most frequent under the new selective pressure. It must be highlighted that 52 
antimicrobial resistance genes could be present in bacteria before the availability of 53 
these drugs (1). Thus, antimicrobial agents are probably only changing the population 54 
dynamics; susceptible versus resistant bacteria. It is a known fact that antimicrobial 55 
resistance could pose a serious risk for human and animal health; and in general, 56 
emergence of resistance reduces the effectiveness of these drugs. 57 
 58 
During the last decade, resistance to extended spectrum beta-lactams, especially third- 59 
and fourth-generation cephalosporins and penems has raised the concern of the 60 
scientific community. The World Health Organization has defined third- and fourth-61 
generation cephalosporins as being “critically important” for use in humans 62 
(http://www.who.int/ foodborne_disease/resistance/cia/en/index.html), since the 63 
increased presence of resistance to these antimicrobials could seriously compromise the 64 
treatment of some life threatening infections, including bacteraemia and meningitis.  65 
 66 
 
 
A third-generation cephalosporin, ceftiofur, and a fourth-generation cephalosporin, 67 
cefquinome, have been developed strictly for veterinary use (2). Ceftiofur is widely 68 
used in many different food animals to treat respiratory diseases. Cefquinome can also 69 
be used for the treatment of mastitis metritis agalaxia syndrome in sows, exudative 70 
epidermitis, and meningitis (3). The systemic use of cephalosporins in food animals that 71 
could potentially select for resistance organisms is worrisome due to the role that food 72 
producing animals may play in the spread of extended spectrum cephalosporins into the 73 
community. 74 
 75 
Previous studies have demonstrated statistically significant association between the use 76 
of ceftiofur and reduced susceptibility to third generation cephalosporins in Escherichia 77 
coli (4, 5). However, they did not find association between ceftiofur usage and presence 78 
of ESBL genes (blaCTX-M) and more importantly, none of these studies have examined 79 
other drug-use practice that can cross- or co-select for cephalosporin resistance. To our 80 
understanding, there is a lack of comprehensive studies performed under standard pig 81 
rearing conditions, analysing the presence and factors that can contribute to both, 82 
emergence and increase in occurrence of CR E. coli in pig farms.  83 
 84 
For this reason, this study intends to evaluate if the treatments with two different beta-85 
lactams, ceftiofur and amoxicillin, are risk factors associated to the emergence of CR E. 86 
coli during two stages (preweaning-growing and finishing) of the rearing period, and 87 
assess if there is enough selective pressure to maintain resistant strains during the life-88 
time of the animals. 89 
 90 
 
 
Materials and Methods 91 
Study design 92 
This study was conducted on a conventional commercial pig farm in the northeast of 93 
Spain. During the six months previous to the study the site remained depopulated, 94 
cleaned and disinfected with standard operation procedures under field conditions. Sixty 95 
eight sows were housed in the climate control house, and faecal samples were collected 96 
to examine the presence of CR E. coli. After farrowing, a total of 100 seven-day-old 97 
piglets from 10 different sows were spatially divided into two groups: untreated control 98 
(n=50) and parenterally treated (n=50) with ceftiofur (5 mg/Kg of body weight in one 99 
shot) following the summary of product characteristics of a commercial presentation 100 
(Naxcel®, Zoetis SLU). Three animals from the control group died of non infectious 101 
causes during the course of the study. Faecal samples were taken manually from the 102 
rectum of piglets in six occasions; before treatment (day 0) and at days 2, 7, 14, 21 and 103 
42 post-treatment (Table 1).  104 
 105 
During the fattening period (day 70), each of the previous groups was subdivided into 106 
two (Table 2). A treatment with amoxicillin (Maymoxi®, Laboratorios Maymó) was 107 
administered in feed for 14 days to two of the new four groups (10 mg/kg of body 108 
weight/day). At that point in time, there were a total of four groups: untreated control 109 
group, or animals that did not receive any treatment with beta-lactams (n=20); group 2, 110 
animals orally treated with amoxicillin during finishing (n=26); group 3, animals 111 
parenterally treated with ceftiofur during preweaning (n=20) and group 4, animals 112 
treated with ceftiofur and amoxicillin (n=26). The four groups remained spatially 113 
separated until their departure to the abattoir. Faecal samples were taken from all 114 
 
 
animals before administration of amoxicillin (day 0) and on days 2, 7, 14, 21 and 45 and 115 
73 post-treatment. A final sampling was performed at slaughter time. During the course 116 
of the study, farm biosecurity was extreme. Animals of different groups were spatially 117 
separated in designated pens to avoid contact. Overboots were used and replaced at the 118 
entrance of each pen. Sampling was always initiated from the control group to the 119 
treated group to minimize transmission of resistant bacteria from pen to pen.  120 
 121 
The study was performed in a commercial farm where the treatments, housing and 122 
husbandry conditions were conformed to the European Union (EU) Guidelines. In 123 
particular, the medicinal product used in this study (Naxcel®) is EU registered 124 
(EU/2/05/053/001), and it was used according to veterinary rules without any additional 125 
requirement. Thus, it was not necessary to comply with ethical standards and approvals 126 
to carry out this experimental work, since it did not require any invasive procedures 127 
(only collection of faecal samples), or management other than the field standards 128 
protocols set by the company. 129 
 130 
E. coli isolation and identification 131 
Faecal samples were transported to the laboratory at 4ºC on the same day of sampling. 132 
Samples were homogenised and 1 g of faeces was dissolved in 10 ml of MacConkey 133 
broth supplemented with ceftriaxone (1 mg/ml). After overnight enrichment at 37 oC, 134 
10µl were plated onto MacConkey agar with ceftriaxone (1 mg/ml). Three colonies for 135 
each plate were stored and one was confirmed as E. coli by Vitek-2 (Biomerieux) and 136 
further characterized.  137 
 
 
 138 
Pulsed field gel electrophoresis and phylotyping 139 
To assess the clonality of the strains and the epidemiological relatedness, all isolates 140 
were analyzed for genetic relatedness by PFGE using XbaI according to the CDC 141 
PulseNet protocol (6). The Salmonella Braenderup H9812 strain was used as molecular 142 
standard. PFGE profiles were compared using Fingerprinting II Informatixe software 143 
(Applied Maths, Sint-Martens-Latem, Belgium). Isolates were considered to have a 144 
unique pattern when at least one band difference was detected. The analysis of the 145 
bands generated was performed using the Dice coefficient and unweighted pair group 146 
method with arithmetic averages (optimization of 1.5% and position tolerance 1.5%). 147 
The isolates were discriminated in pyhlogenetic groups (A, B1, B2, C, D and E) 148 
according to the method previously described by Clermont et al. (7, 8) 149 
 150 
Antimicrobial susceptibility testing 151 
Disc diffusion was performed according to CLSI guidelines using the following discs 152 
(Oxoid, UK): cefoxitin, 30 mg; cefepime, 30 mg; ceftazidime, 30 mg; cefotaxime, 30 153 
mg; cefotaxime+clavulanic acid, 30+10 mg; and ceftazidime+clavulanic acid, 30+10 154 
mg. The disc combinations of cefotaxime and cefotaxime/clavulanic acid, ceftazidime 155 
and ceftazidime/clavulanic acid were used for the identification of ESBLs; cefoxitin 156 
was used for the detection of ampC-type beta-lactamase (9). Minimum inhibitory 157 
concentration (MIC) against ampicillin, ciprofloxacin, nalidixic acid, gentamicin, 158 
streptomycin, tetracycline, florfenicol, colistin sulphate, sulphametoxazole, 159 
trimethoprim, chloramphenicol, kanamycin, cefotaxime and ceftazidime was 160 
determined by microdilution methods (VetMIC GN-mo, National Veterinary Institute, 161 
 
 
Uppsala, Sweden). Results were interpreted as epidemiological cut-off values following 162 
EUCAST recommendations.  163 
 164 
Detection of resistance genes 165 
Resistance to third-generation cephalosporins was analysed by PCR for the presence of 166 
the blaTEM, blaCTX, blaCMY-1, blaCMY-2 and blaSHV, genes as described previously (10). 167 
Detection of plasmid-mediated AmpC beta-lactamase genes was assessed by multiplex 168 
PCR (11). Sequence analysis was performed using Vector NTI advance 11 (InforMax, 169 
Inc., Bethesda, MD). The amplified nucleotide sequences were compared to previously 170 
described sequences obtained from public databases (www.ncbi.nlm.nih.gov, 171 
http://www.lahey.org/Studies/). 172 
 173 
Mating experiments and plasmid characterization 174 
Filter mating experiments were performed to assess the capacity of the plasmids to 175 
conjugate. For this analysis, fourteen strains containing ESBL genes were selected. 176 
They comprised representative isolates from five PFGE clusters and nine PFGE types. 177 
Mating assays were performed as described elsewhere (12), using the strains as donors 178 
and rifampicin-resistant E. coli HB101 as recipient. Transconjugants were selected on 179 
LB agar plates containing rifampicin (50 mg/L) and ceftriaxone (1mg/L) and were 180 
confirmed by PFGE. 181 
 182 
 
 
Plasmidic DNA was purified from these 14 wild-type isolates and later from 183 
transformants using a Qiagen Plasmid Midi Kit (Qiagen, Hilden, Germany) according to 184 
the manufacturer's recommendations. Plasmids were introduced to electrocompetent 185 
plasmid-free E. coli cells by electroporation. Transformants were selected in brain heart 186 
infusion agar supplemented with ceftriaxone (1mg/L) and PCR for confirmation of the 187 
cephalosporin resistant genes was performed. The presence of a unique plasmid in the 188 
transformants and their sizes were determined using S1-PFGE (13). Finally, plasmids 189 
were classified by PCR-based replicon typing (14). Additionally, susceptibility testing 190 
was performed in all transformants to assess transferability of resistance genes unrelated 191 
to cephalosporins.  192 
 193 
Results 194 
Emergence of cephalosporin resistance during treatment 195 
All 68 sows were negative for CR E. coli. However, before administration of ceftiofur, 196 
five and seven of the seven-day-old piglets among the control and the treated groups 197 
respectively, yielded CR E. coli (Table 1). During this first treatment, a total of 12 198 
(4.1%) and 23 (8%) CR E. coli were isolated from the control (n=288 samples) and the 199 
treated group (n=300 samples), respectively. The difference in the proportion of CR E. 200 
coli recovered in the two groups was statistically significant (p=0.04). The highest 201 
percentage of samples positive for CR E. coli was obtained within the treated group 202 
(22%), 48 hours post-treatment, showing a statistical tendency (p=0.1) when compared 203 
to the corresponding figure (10%) of the control group.  204 
 205 
 
 
A total of 552 faecal swabs were collected during the second part of the study when 206 
animals were treated with amoxicillin in-feed (Table 2). Previously to the treatment 207 
with amoxicillin, all animals were negative for CR E. coli. Two, seven, one and one CR 208 
E. coli were recovered from group 2 (treated only with amoxicillin) after 2, 7, 14 and 45 209 
days post-treatment, respectively. One extra isolate was obtained from group 4 (treated 210 
with ceftiofur and amoxicillin) after 21 days post-treatment. No other positive samples 211 
were obtained in the rest of the groups during the study period. The highest percentage 212 
of samples positive for CR E. coli (27%) was obtained after seven days of amoxicillin 213 
treatment, within the group treated with amoxicillin and with no previous history of 214 
ceftiofur use. Significant differences were observed (Fisher test, p=0.02) between the 215 
proportion of CR E. coli isolated from animals treated with amoxicillin and the rest of 216 
the groups after seven days of treatment. By the finishing time, all animals were 217 
negative for CR E. coli.  218 
 219 
PFGE and phylogenetic analysis 220 
Electrophoresis of XbaI-digested genomic DNA from the 47 CR E. coli isolates 221 
revealed 22 different profiles (Fig. 1). XbaI profiles typically had 14 to 21 restriction 222 
fragments between 20 and 1135 kb (Fig. 1). Indistinguishable fingerprints were present 223 
in isolates from different animals, and also in isolates obtained from the same animal at 224 
different sampling times (annex 1), indicating the persistence of clones during the 225 
course of the treatment. Interestingly, none of the clones obtained during the treatment 226 
with ceftiofur were recovered during treatment with amoxicillin. Additionally, 10 out of 227 
12 isolates recovered during amoxicillin treatment presented identical PFGE pattern. A 228 
 
 
total of 66%, 25%, 4% and 4% belonged to the phylogroups A, B1, C and E, 229 
respectively. 230 
 231 
MIC determination 232 
All 47 CR E. coli isolates (Figure 1) were resistant to ampicillin (WT ≤ 8mg/L) and 233 
cefotaxime, (WT ≤ 0.25 mg/L) and all but four (belonging to the ceftiofur study) were 234 
resistant to ceftazidime (WT ≤ 0.5 mg/L). Regarding the remaining antimicrobial 235 
families tested (tetracyclines, sulphamides, trimethoprim, aminoglycosides, quinolones, 236 
phenicols and polymyxins), all isolates but two were multiresistant (15), ranging from 237 
resistance to three families of antimicrobials to resistance to six. MIC differences were 238 
detected among isolates according to treatment and sow. Higher levels of resistance 239 
were found during the ceftiofur treatment against phenicols (both, chloramphenicol 240 
(WT ≤ 16 mg/L) and florfenicol (WT ≤ 16 mg/L)) and gentamicin (WT ≤ 2 mg/L) when 241 
compared to the amoxicillin treatment, whereas levels of resistance were lower against 242 
ciprofloxacin (WT ≤ 0.064 mg/L), nalidixic acid (WT ≤ 16 mg/L), trimethoprim (WT ≤ 243 
2 mg/L), and kanamycin (WT ≤ 8 mg/L). Litter from sow number 25 had all 10 positive 244 
CR isolates but one with the same resistance phenotype (beta-lactams – quinolones - 245 
trimetophim), whereas the remaining isolates obtained from the rest of the sows 246 
exhibited higher diversity of resistance traits. One isolate was resistant to colistin (WT ≤ 247 
2 mg/L). 248 
 249 
Detection of genes responsible for ESBL resistance 250 
 
 
ESBL genes were detected in 36 of these 47 CR E. coli strains, and in most cases were 251 
combined with the blaTEM-1 gene. Fifteen strains were confirmed to contained blaCTX-M-252 
1, 10 blaCTX-M-14, four blaCTX-M-9, two blaCTX-M-15 and five blaSHV-12. Four isolates were 253 
resistant to cefoxitin and the genotype could not be determined. Seven isolates with 254 
MIC 0.5 mg/L and 2 mg/L for cefotaxime and ceftazidime respectively, were negative 255 
for all PCRs tested, suggesting low susceptibility to cephalosporins probably by 256 
upregulation of the AmpC promoter. 257 
 258 
Conjugation and transformation 259 
Eight of the 14 selected strains were able to transfer the cephalosporin resistant genes by 260 
conjugation. Additionally, 11 out of 14 strains transferred cephalosporin resistant genes 261 
to the electrocompetent strain. The 11 transformants together with the three 262 
transconjugants resulting from the wild-type strains were subjected to S1-nuclease, and 263 
the presence of one unique plasmid was confirmed. Sizes of plasmids varied between 264 
aprox. 33.4 Kb and 173.4 Kb (Table 3). IncI1 was the most common replicon followed 265 
by IncN. Four of the strains presented two different replicons on the same plasmid, and 266 
no replicons were detected in one of the transformants.  267 
 268 
The transformants/transconjugants were also resistant to streptomycin (n=10), 269 
tetracycline (n=9), sulphamethosaxole (n=8), trimethoprim (n=4), ciprofloxacin (n=2), 270 
and kanamycin (n=1).  271 
Discussion 272 
 
 
Cephalosporin resistant E. coli strains were found in samples from seven-day old piglets 273 
prior receiving any medication. Moreover, we could not detect them from the sows 274 
despite using an enrichment step for isolation of the specific resistance trait. The high 275 
clonality of the isolates demonstrated by PFGE does not plead for a vertical 276 
transmission, but rather for multiple acquisitions of strains with limited colonization 277 
properties, perhaps from an external origin (personnel working at the farm, food source, 278 
presence of rodents or other vectors). Other studies have also detected high diversity of 279 
CR strains in newborn piglets (16). Further identification of the possible sources of 280 
contamination to prevent the entrance of resistant bacteria into the farm should be 281 
carried out. On the other hand, in some cases, PFGE results suggest that some of the 282 
clones were shared among piglets of the same pen (like the litters from sows numbers 283 
25 and 11, see annex 1), indicating a common source within the pen. Perhaps the 284 
mothers were colonized with CR E. coli but the limitation of the bacteriological 285 
techniques did not allow their detection. Hence, the farm was cleaned and depopulated 286 
during the six months previous to the study; incorrect cleaning and disinfection of the 287 
premises may play a role in the persistence of these organisms. Since environmental 288 
samples of the barn were not taken prior the study, this option cannot be ruled out. 289 
Thus, a further visit to this farm, after one year of finishing this trial and applying a 290 
cleaning and disinfection protocol, demonstrated the presence of CR E. coli in the 291 
environment with a different PFGE profile to the ones isolated from faeces (data not 292 
shown).  293 
 294 
After 48 hours of the parenteral treatment with ceftiofur, an increase in the prevalence 295 
of CR E. coli was detected. These levels decreased after the first week of treatment. In 296 
the case of in-feed amoxicillin treatment, similar increase was observed after seven days 297 
 
 
of treatment. In the last visit, prior departure to the abattoir, all the animals were 298 
negative for CR E. coli. Results from this study are in agreement with other studies 299 
performed in calves (17, 18), in which CR E. coli emerged for short time while 300 
treatment was in course, and diminished shortly after treatment. Perhaps the resistant 301 
population could not compete well with the sensitive population after withdrawal of the 302 
antibiotic (17). However, during treatment with beta-lactam antimicrobials, animal 303 
faeces could become a source of resistant bacteria. Biosecurity measures should be 304 
undertaken during treatment, such as faeces removal or isolation of animals under 305 
medication to avoid transfer of resistance. Additionally, farmers are at potential risk of 306 
contamination during exposure to animals shedding CR bacteria. Studies have 307 
demonstrated that ESBL genes and plasmids obtained from E. coli of farmers, exhibited 308 
genetic similarity to those obtained from E. coli isolated from animals belonging to their 309 
farms (19). 310 
 311 
It is interesting to notice the emergence of new clones of CR E. coli within the group 312 
treated only with amoxicillin and without previous history of ceftiofur use. One would 313 
expect that the second treatment would re-select the same clones that emerged during 314 
the first treatment, but that was not the case. Out of 12 CR E. coli isolates obtained 315 
during the second treatment, nine belonged to the same clonal group by PFGE and 316 
presented the same cephalosporin resistance genes, blaCTX-M-14; whereas the two extra 317 
isolates clustered alone and contained blaCTX-M-1 and blaSHV-12. A recent study by 318 
Hansen et al (16) has described a reduction in the diversity of CR strains during the life 319 
cycle, which is at a first glance what our results suggest. However, these conclusions 320 
cannot be drawn based on our study, since one unique CR E. coli isolate per animal has 321 
 
 
been characterized and therefore, some of the resistant isolates from the first application 322 
of the drug could have been missed in the second round of sampling.  323 
 324 
It appears that both treatments with beta-lactams have selected for a wide range of 325 
cephalosporin resistance genes from different families, and these genes were recovered 326 
during both treatments. Previous studies analyzing the presence of cephalosporin 327 
resistance genes in pig farms in Spain, described the presence of different bla genes 328 
with SHV-12 being the most frequent (20), a completely different picture to other 329 
European countries where SHV-12 is associated to human infections (21). Results from 330 
this study have shown the co-existence of many different resistant genes within one 331 
farm. The most frequent CTX-M variants in ESBL producers in animals and food of 332 
animal origin are currently CTX-M-1 and CTX-M-14, while CTX-M-15 ESBL-333 
producing E. coli have only exceptionally been observed in the veterinary context (22). 334 
However, this study has demonstrated the presence of CTX-M-15 genes in healthy pigs 335 
harboured in high molecular weight plasmids of aprox. 150 Kb containing two 336 
replicons; FIA and FIB. Are we seeing a similar change in the evolution of resistance 337 
than we have perceived in the human side (23), where it was a shift in occurrence from 338 
CTX-M-14 and CTX-M1 towards CTX-M15?  339 
 340 
Specific bacterial strains are more successful at colonizing individual animals. That 341 
appears to be the case of one animal (number 29) shedding the same resistant clone 342 
during the first 20 days of life. Even though CR E. coli were isolated from this same 343 
animal at mature age (138 days), PFGE demonstrated the presence of a different clone; 344 
however, in all cases the isolates yielded blaCTX-M-1. Transformation experiments and 345 
 
 
replicon typing revealed the presence of a great variety of plasmids of many different 346 
sizes harbouring the same resistant genes, with the most common replicons being IncI1 347 
and IncN. However, further studies should be performed at the animal level and at the 348 
farm level to assess both, the occurrence and spread of plasmids within the pig bacterial 349 
population in a particular farm, and the persistence and transmission of these plasmids 350 
from herd to herd.  351 
 352 
Additionally, CR E. coli recovered during the course of the study were phenotypically 353 
resistant to different families of antimicrobials and half of them were resistant to 354 
ciprofloxacin, even though fluoroquinolones were never used to treat these animals. 355 
Although fluoroquinolone resistant is mostly conferred via gyrA/parC mutation in the 356 
bacterial chromosome, two of the transformants exhibited resistance to 357 
fluoroquinolones. Plasmid mediated quinolone resistance has been in some cases 358 
associated to the same plasmids as those harbouring cephalosporin resistance genes 359 
(24). Furthermore, as demonstrated by the phenotype of the transformants exhibiting 360 
resistance to several antimicrobial families, co-selection by plasmids bearing resistance 361 
genes for different antimicrobial families probably plays an important role in the 362 
maintenance of resistance mechanisms. In depth studies should be performed to avoid 363 
the transmission of these resistance genes from farm to fork, since several studies have 364 
demonstrated the presence of resistant E. coli and in particular CR E. coli of pig origin 365 
in the abattoir (25-27). Although animals from this study departed to the abattoir free of 366 
CR E. coli, it should be notice that this study was conducted under control conditions 367 
and no extra-medication apart from ceftiofur and amoxicillin was applied during the 368 
course of the study. However, conventional farming could also require the 369 
administration of macrolides, polymyxins and tetracyclines during the fattening period, 370 
 
 
which could co-select for CR E. coli (28, 29). Nowadays, there are a scarce data linking 371 
antimicrobial consumption in veterinary medicine and the generation of antimicrobial 372 
resistance bacteria; hence, it seems clear that the use of different families of 373 
antimicrobials in the same population could be a risk factor for the development of 374 
antimicrobial resistance in several microorganisms under field conditions (30). 375 
 376 
Taken together these results suggest that the use of ceftiofur and amoxicillin at different 377 
stages of the rearing cycle are independent risk factors for the selection of CR E. coli. 378 
Both beta-lactam antimicrobials do select for resistant E. coli during the course of the 379 
treatment. However, CR E. coli appear to be transitory and disappear in the absence of 380 
the selective pressure. Both treatments did not select for long-term resistant organisms 381 
since we could not detect CR E. coli when the animals departed to the abattoir. 382 
However, further studies should be designed to identify other risk factors associated to 383 
the persistence of resistance determinants to minimize the recirculation of strains and/or 384 
plasmids within farms. 385 
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Table 1: Results obtained during the visits after treatment with ceftiofur. Sampling in 496 
day 0 was performed prior injecting the animals with ceftiofur. 497 
Sampling 
days 
Age 
(days) 
Positive animals in the 
control group (N=50*) 
Positive animals in the 
treated group (N=50) 
0 6-8 5 (10%) 7 (12%) 
2 8-10 5 (10%) 11 (26%) 
7 13-15 1 (2%) 0 
14 20-22 1 (2%) 5 (8%) 
21 27-29 0 0 
41 47-49 0 0 
*three animals from the control group died after 7 days of treatment decreasing the size 498 
of the group to 47 animals. 499 
  500 
 
 
Table 2: Results obtained during the course of the study after treatment with 501 
amoxicillin. Sampling in day 0 was performed just before the beginning of the 502 
treatment.  503 
  Positive animals in each group 
Sampling 
days 
Age 
(days) 
Group 1 
(N=20) 
Group 2 
(N=26) 
Group 3 
(N=20) 
Group 4 
(N=26) 
0 70 0 0 0 0 
2 72 0 2 (8%) 0 0 
7 77 0 7 (27%) 0 0 
14 84 0 1 (4%) 0 0 
21 115 0 0 0 1 (4%) 
45 138 0 1 (4%) 0 0 
73 155 0 0 0 0 
Group 1: untreated with antimicrobials, Group 2: untreated with ceftiofur and treated 504 
with amoxicillin, Group 3: treated with ceftiofur and not treated with amoxicillin, 505 
Group 4: treated with ceftiofur and with amoxicillin. 506 
 507 
 508 
 509 
 
 
Figure 1. Dendogram showing the genotypic relatedness of the CR E. coli isolated during the course of the study, phylogeny, cephalosporin 510 
resistance genes, treatment and phenotypic diversity. 511 
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control
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Am: ampicillin, Ci:ciprofloxacin, Nal: nalidixic acid, Gm: gentamicin, Sm: streptomycin, Tc: tetracycline, Ff: florfenicol, Cs: colistin, Su: Sulphametoxazole, Tm: trimethoprim, Cm: chloramphenicol, Km: kanamycin, 522 
Ctx: cefotaxime, Caz:ceftazidime.  523 
Underlined are those strains selected for transformation and conjugation experiments 524 
 525 
 
 
Table 3: Results of the conjungations and transformations experiments together with 526 
plamid replicons, and plasmids sizes obtained.  527 
 Inc Families found 
Wild type 
Resistance 
gene 
Conjugation 
results 
Transformation 
results I1 N FIA FIB A/C 
Molecular 
Weight (Kb) 
E1V1C17a CTXM-14 TC1b TF1a + 120 
E1V1C80a SHV-12 TC2a + 138,9 
E1V1C63a CTXM-9 TC3b + 138,9 
E1V4C80a CTXM-1 TC4a TF4a + 40 
E1V4C29b CTXM-1 TF5a + + 140 
E1V2C30a CTXM-1 TF6a + 138 
E1V1C96a CTXM-1 TC7a TF7a + 40 
E1V1C59a SHV-12 TC8c TF8 + + 180 
E1V1C65a CTXM-1 TF9a + 50 
E2V6C29c CTXM-1 TC10a TF10a + 180 
E2V5C75c SHV-12 TF11a 140 
E1V4C89c CTXM-15 TF12a + + 150+ 
E2V3C47b CTXM-15 TF13a + + 150 
E2V2C31a CTXM-14 TC14a + 120 
In bold all transconjugants and transformants used for replicon typing 528 
